OBJECTIVES The aim of this study was to evaluate patient-reported and physician-assessed atrial fibrillation (AF)-related symptoms after AF ablation.
AF with minimal or no structural heart or other serious disease. The most common success criterion has been freedom from documented recurrence of AF or other atrial tachyarrhythmias of more than 30 s in duration (1) (2) (3) . In determining the impact before and after ablation on symptoms and healthrelated quality of life, generic rather than AF-specific questionnaires have often been used (4) .
However, although the main purpose and indication for AF ablation is to reduce symptoms, the absence or reduction of AF recurrence, regardless of the definition and mode of follow-up, may not be an optimal success criterion alone, because it does not reflect what symptomatic patients experience.
Electrocardiographic recordings are reliable in detecting AF, but symptoms are not, even if the patient suspects or believes that the symptoms are caused by the arrhythmia (5) . In addition, AF ablation may also change the perception of AF so that a patient may experience diminished symptoms despite recurring episodes of arrhythmia (6, 7) . Studies also suggest that physicians may underestimate patient symptoms, especially when they are mild (8, 9) .
We hypothesized that patients and physicians may rate the change in symptoms after ablation differently. The aim of this study was to evaluate patient-reported and physician-assessed AF-related symptoms up to 2 years after AF ablation and to identify whether they were correlated, in relation to the AF burden continuously measured by an implantable loop recorder (ILR).
METHODS

PATIENTS.
Patients were enrolled at 2 Scandinavian university hospitals and were eligible if they had: 1) documented symptomatic paroxysmal or persistent AF (<3 months) and were planned for catheter ablation; and 2) were 30 to 70 years of age. Important exclusion criteria were: 1) left atrial diameter >60 Patients were implanted with an ILR (Reveal XT, Medtronic, Minneapolis, Minnesota) in the left parasternal area at least 2 weeks before the ablation that remained for a minimum of 24 months after ablation.
The autoactivation and the AF detection algorithm were programmed to ON, which classifies the heart rhythm as AF when the R-R intervals within a 2-min period show a certain pattern of uncorrelated irregularity (10) . Patients were also encouraged to start manually triggered 30-s rhythm recordings during perceived arrhythmia symptoms using the patient activator. The ILR was programmed to provide, over time, the number of arrhythmia episodes, their duration, and, when all durations of AF episodes were added, the AF burden.
CATHETER ABLATION PROCEDURE. The catheter ablation procedure has been reported previously (11) and consisted of circumferential radiofrequency lines around each pair of pulmonary vein ostia in the left atrium. Reablation was permitted at the investigator's discretion without excluding the patient from the study.
PATIENT-REPORTED OUTCOMES. Symptoms were assessed using the AF-specific questionnaire AF6, which has undergone thorough validation (12) and testing of clinical responsiveness (13) and includes a recall period of the most recent 7 days. This 6-item questionnaire includes patient-reported AF-related symptoms: item 1, "breathing difficulties at rest"; item 2, "breathing difficulties upon exertion"; item 3, "limitations in day-to-day life due to AF"; item 4, "feeling of discomfort due to AF"; item 5, "tiredness due to AF"; and item 6, "worry/anxiety due to AF."
A score of 0 (no symptoms) to 10 (severe symptoms) is reported for each item, and all scores are added into a single sum score. Sum scores range from 0 to 60, with higher values reflecting more severe AF-related symptoms. After initial instruction, the questionnaire was completed by the patient without interaction from physicians or nurses and before the electrocardiogram was recorded to document the actual cardiac rhythm.
The AF6 questionnaire was completed before and 6, 12, and 24 months after ablation. EHRA class was noted before and 6, 12, and 24 months after ablation.
AF BURDEN. The AF burden composed of adjudicated AF episodes was calculated from the ILR data as the percentage of time in AF between each follow-up visit, as previously described. In addition to correlating the AF burden with symptom scores, we applied a previously suggested AF burden cutoff limit of 0.5% at each scheduled visit to define success of AF ablation (11, 15 Fisher exact test was used as appropriate. We assessed the correlation of AF6 score before and after ablation using the Pearson correlation coefficient (r) and all correlations involving AF burden, because of non-normality, and EHRA class, because of the ordinal scale, using the Spearman rank correlation coefficient (r). We also estimated the predictive ability by calculating the correlation coefficient squared 
RESULTS
BASELINE DEMOGRAPHICS. Fifty-nine patients were screened, 1 withdrew consent, and 1 patient was excluded because of a lack of a correlation between AF and symptoms. Fifty-seven patients underwent AF ablation and constituted the study population. Their mean age was 57 AE 9 years, and 40% were women.
The most common comorbidities were hypertension (42%) and previous stroke or transient ischemic attack (14%) ( Table 1) . Fifty-four patients completed the 24-month follow-up. Twenty-three patients (43%) underwent reablation during follow-up.
PATIENTS' ASSESSMENT OF AF-SPECIFIC SYMPTOMS BEFORE AND AFTER ABLATION. Before ablation, AF6 items 1 to 6 scored $1 point in 54%, 83%, 83%, 91%, 85%, and 89% of the patients, respectively, and in 30%, 59%, 54%, 52%, 54%, and 54% of the patients at 24 months. The most severe symptom before ablation was tiredness due to AF, which scored a median of 7 of a maximum of 10 points ( Table 2) . When symptoms persisted at 24 months, the most important item was the same but showed statistically significantly reduced scores. All items on the AF6 and the sum score decreased statistically significantly over the 24-month follow-up period. The median AF6 scores improved from before ablation to 6 months after ablation and further to 12 months for all items and the sum score, except for item 1, and remained at this level at 24 months after ablation.
The AF6 sum score at all times after ablation correlated significantly with the AF6 sum score before and 24 months after ablation, respectively).
There were 11 (20%), 12 (22%), and 16 (30%) patients, respectively, who reported no symptoms at all (AF6 score 0) at 6, 12, and 24 months after ablation.
Five patients (9%) did not report any symptoms at any time after ablation.
The mean AF6 sum score was 29.5 AE 13.9 before ablation. The mean difference in the AF6 sum score from before ablation was 9.3 (95% confidence interval: 5.2 to 13.4; p < 0.001) at 6 months after ablation, 16 .6 (95% confidence interval: 12.2 to 20.9; p < 0.001) at 12 months, and 13.6 (95% confidence interval: 9.0 to 18.3 (p < 0.001) 24 months after ablation, corresponding to Cohen effect sizes of 0.67, 1.2, and 0.98, respectively. Thus, effect sizes were moderate to large after ablation. An improvement of more than 9 points was therefore considered clinically meaningful and was seen in 25 patients (50%) at 6 months, 33 patients (75%) at 12 months, and 30 patients (61%) at 24 months after ablation.
PHYSICIANS' EVALUATION OF SYMPTOMS BEFORE AND
AFTER ABLATION: EHRA CLASSIFICATION. EHRA class improved statistically significantly over the 2-year follow-up period, and at 6, 12, and 24 months after ablation, 76%, 70%, and 82% of patients, respectively, were in EHRA class I ( Table 2 ). The greatest improvement was seen during the first 6 months after ablation, with no further improvement beyond that period. EHRA class most often improved by 1 class (from II to I, n ¼ 20; from III to II, n ¼ 1) and less often by 2 or 3 classes (from III to I, n ¼ 10;
from IV to I, n ¼ 1).
Nineteen patients (35%) were already categorized in EHRA class I before ablation, and 9 of them were also considered to be in EHRA class I at all times after the ablation. The remaining 10 patients varied from EHRA class I to III after ablation; at 24 months, 4 patients were in EHRA class I, 4 in EHRA class II, and 2 in EHRA class III. The changes in AF6 sum score and EHRA class from before ablation were visualized with scatterplots at 6 (r ¼ 0.31, r 2 ¼ 0.10; p ¼ 0.02), 12 (r ¼ 0.32, r 2 ¼ 0.10; p ¼ 0.03), and 24 months (r ¼ 0.22, r 2 ¼ 0.05; p ¼ 0.12) after ablation (Figures 2A to 2C) . In Figure 2A , 25 patients decreased in AF6 sum score by more than 9 points, and nearly two-thirds of them also had a 1-or 2-class change in EHRA score. However, 12 patients had smaller changes in AF6 sum score, and one-third of them still had 1-or 2-class EHRA score changes, implying that physicians had a more positive interpretation of symptom improvement than patients.
Patients considered to be improved in EHRA class had statistically significantly lower median AF6 sum scores of 1 (IQR: 0 to 4), 6 (IQR: 0 to 13), and 5 (IQR: 0 to 28) at 6, 12, and 24 months after ablation, respectively, compared with patients with unchanged or worse EHRA class with median AF6 sum scores of 40 (IQR: 27 to 46; p ¼ 0.003), 31 (IQR: 12 to 39; p ¼ 0.001), and 36 (IQR: 28 to 36; p ¼ 0.02).
The 19 patients (paroxysmal AF, n ¼ 15; persistent AF, n ¼ 4) considered to be in EHRA class I before ablation had a median AF6 sum score of 24 (IQR: 14 to 34) before ablation. The most common AF6 items were limitations in day-to-day life due to AF and worry/anxiety due to AF, while the highest scoring item was tiredness due to AF.
EFFECT OF ABLATION ON AF OVER TIME IN RELATION TO
SYMPTOMS. The proportion of patients with AF burden of 0% during the past 6-month period was 26%, 43%, and 43% at 6, 12, and 24 months after ablation, increasing to 46%, 56%, and 65% if an AF burden cutoff of #0.5% was applied. The proportion of patients with AF burden #0.5% increased from before ablation to 6 (p ¼ 0.01), 12 (p ¼ 0.01), and Values are median (interquartile range) or n (%). All 6 items in the AF6, the AF6 sum score, and EHRA class improved significantly over time. AF6 item 1, "breathing difficulties at rest"; item 2, "breathing difficulties upon exertion"; item 3, "limitations in day-to-day life due to AF"; item 4, "feeling of discomfort due to AF"; item 5, "tiredness due to AF"; and item 6, "worry/anxiety due to AF." A score of 0 (no symptoms) to 10 (severe symptoms) is reported for each item, and all scores are added to give a single sum score of 0 to 60. EHRA class I (no symptoms), II (mild symptoms), III (severe symptoms), or IV (disabling symptoms). *1 patient missing. †5 patients missing. ‡1 patient missing. §Statistically significant (p < 0.05).
AF ¼ atrial fibrillation; EHRA ¼ European Heart Rhythm Association. AF-Specific Symptoms and AF Ablation 24 (p ¼ 0.004) months after ablation. There was a small but not significant decrease in median AF burden over time (11) .
The AF6 sum score was significantly correlated with AF burden at 6 (r ¼ 0.37; p < 0.01), 12 (r ¼ 0.62; p < 0.01), and 24 (r ¼ 0.52; p < 0.01) months after ablation. When the AF burden cutoff of >0.5% was applied, there was also a significant association with higher AF6 sum scores at all times after ablation (Figure 3) . EHRA class and AF burden were significantly correlated at 
DISCUSSION
In the present study, patients were followed by patient-reported symptoms using the AF6 and physician-assessed EHRA class for 2 years after AF ablation with complete knowledge of the underlying rhythm. AF ablation led to long-lasting symptom relief as perceived both by patients and by physicians, and AF burden correlated with both AF6 sum score and EHRA class, especially when AF burden was low. However, there was often a discrepancy between AF6 sum score and EHRA class, implying that physicians were more likely to indicate improvement in terms of a better EHRA class, while the AF6 appeared to be a more sensitive tool. Complete freedom from AF did not preclude that patients felt some symptoms, while patients with AF burden up to 10% at 24 months indicated symptomatic reduction after ablation.
PATIENT-REPORTED
OUTCOMES USING THE AF6. Disease-specific questionnaires have been developed for AF but have not often been used after ablation. We used the AF-specific AF6 and demonstrated significantly lower AF6 scores 24 months after ablation compared with before, which is in line with previous studies using disease-specific assessment tools (17, 18) . The AF6 sum scores before and after ablation were correlated; that is, the patients with the highest scores before ablation also had the highest scores after ablation, which still allowed considerable reductions in the scores. Using the Cohen effect size, we found a reduction of more than 9 points to represent a moderate effect size, which we accepted as a clinically meaningful change and was observed in more than one-half of the patients during follow-up. In patients with AF recruited from tertiary care facilities, Dorian et al. II  I  27  27   11  9%  II  I  16  21   12  9%  II  I  53  28   13  18%  I  I  41  -14  27%  I  III  21  26   15  71%  III  III  40  38   16  100%  I  II  36  20   17  100%  II  I  31  30   18  100%  II  II  47  28   19  100%  I  II  17  20 AF ¼ atrial fibrillation; EHRA ¼ European Heart Rhythm Association. STUDY LIMITATIONS. The study population was small, but all patients were followed in great detail for a minimum of 2 years, and our conclusions should be considered hypothesis generating. The ILR was implanted only a few weeks before ablation, and the AF burden before ablation may therefore not be entirely reliable. The AF6 was formally validated using a recall period of 7 days, while no such period has been indicated for EHRA class, meaning that any AF-Specific Symptoms and AF Ablation comparison or correlation of such results must be made with caution.
CONCLUSIONS
Patient-reported and physician-assessed outcomes both correlated with AF burden after AF ablation, but there were frequent discrepancies between patients and the physicians, especially at higher AF burdens.
Freedom from AF and a low AF burden resulted most often in a reduction of symptoms, but symptom relief also occurred despite little effect on the arrhythmia.
A short, validated AF-specific symptom score such as the AF6 may provide greater patient input to the evaluation of treatment for AF.
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